{"id":"Z13","lang":"zh","question":"逸達的 FP-001 和 CAMCEVI 是同一個產品嗎？美國由誰銷售？","answer":[{"text":"FP-001 是逸達 CAMCEVI 的開發代號；2022 年美國上市公告將 CAMCEVI 42 毫克六個月針劑對應為 FP-001 50 毫克。","fact_ids":["f1"]},{"text":"公告指出它用於晚期前列腺癌，美國市場銷售由 Intas 的美國子公司 Accord BioPharma 負責。","fact_ids":["f2","f3"]}],"facts":[{"id":"f1","claim":"代號與商品對應","value":"CAMCEVI 42 mg 六個月針劑＝FP-001 50 mg","as_of":"2022-04-04","source":"https://www.foreseepharma.com/tw/news/category/%E6%96%B0%E8%81%9E%E7%99%BC%E4%BD%88/accord_biopharma__in_partnership_with_foresee_pharmaceuticals__launches_camcevi___leuprolide__injection_emulsion_in_the_u_s__for_the_treatment_of_advanced_prostate_cancer_in_adults","quote":"即FP-001 50毫克"},{"id":"f2","claim":"用途","value":"晚期前列腺癌","as_of":"2022-04-04","source":"https://www.foreseepharma.com/tw/news/category/%E6%96%B0%E8%81%9E%E7%99%BC%E4%BD%88/accord_biopharma__in_partnership_with_foresee_pharmaceuticals__launches_camcevi___leuprolide__injection_emulsion_in_the_u_s__for_the_treatment_of_advanced_prostate_cancer_in_adults","quote":"治療晚期前列腺癌"},{"id":"f3","claim":"美國銷售公司","value":"Accord BioPharma（Intas 美國子公司）","as_of":"2022-04-04","source":"https://www.foreseepharma.com/tw/news/category/%E6%96%B0%E8%81%9E%E7%99%BC%E4%BD%88/accord_biopharma__in_partnership_with_foresee_pharmaceuticals__launches_camcevi___leuprolide__injection_emulsion_in_the_u_s__for_the_treatment_of_advanced_prostate_cancer_in_adults","quote":"由Accord BioPharma 負責CAMCEVI於美國之市場銷售"}],"undisclosed":{"text":"本卡核對的公開上市公告沒有揭露美國授權的精確銷售權利金比率。","source":"https://www.foreseepharma.com/tw/news/category/%E6%96%B0%E8%81%9E%E7%99%BC%E4%BD%88/accord_biopharma__in_partnership_with_foresee_pharmaceuticals__launches_camcevi___leuprolide__injection_emulsion_in_the_u_s__for_the_treatment_of_advanced_prostate_cancer_in_adults","as_of":"2026-10-22","quote":"2021年3月與Intas Pharmaceuticals簽訂美國市場授權合作","scope":"Only the specific primary documents cited in this card were checked; absence is not a claim about all public disclosures."},"verified_at":"2026-10-22","coverage":"answered"}